Literature DB >> 24914351

Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR.

Marzieh Jamalidoust1, Mandana Namayandeh1, Sadaf Asaei1, Nasrin Aliabadi1, Mazyar Ziyaeyan1.   

Abstract

AIM: To assess hepatitis C virus (HCV) genotype patterns among high-risk Iranian groups, using real-time RT-PCR.
METHODS: In this study, we evaluated the distribution of different HCV genotypes among injection drug users and other high-risk groups over a 4-year period (from 2009 to 2012) using real-time polymerase chain reaction (PCR). Sera from 888 HCV-infected patients residing in southern and southwest Iran were genotyped using real-time PCR with common primers and specific probes. These patients were grouped into distinct exposure categories. Illicit drug users constituted the primary group and were further evaluated for HCV genotype distribution and parameters such as age range.
RESULTS: Of the examined HCV-infected patients, 62% were substance abusers, although the route of transmission could not be determined in approximately 30% of these patients. HCV genotyping revealed that Gt1 was the most prevalent genotype among the drug users as well as among patients with thalassemia, hemophilia, solid organ recipients and those on hemodialysis. Mixed infections were only seen in addict groups, where Gt2 genotype was also found. The highest frequencies in HCV-positive addict patients were observed in the 31-40 age group. Our research also showed that the addiction age has increased, whereas the addiction rate has dropped in this region. Most illicit drug users had more than one risk factor such as tattoo and/or a history of imprisonment.
CONCLUSION: This study revealed that the most common HCV-infection route and HCV-genotype in southern and southwest Iran was illicit drug abuse and Gt1, respectively.

Entities:  

Keywords:  Hepatitis C virus genotype distribution; Injection drug users; Iran; Real-time PCR

Mesh:

Year:  2014        PMID: 24914351      PMCID: PMC4024800          DOI: 10.3748/wjg.v20.i19.5897

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

Review 1.  Hepatitis C treatment for injection drug users: a review of the available evidence.

Authors:  Margaret Hellard; Rachel Sacks-Davis; Judy Gold
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

2.  Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time.

Authors:  Katayoun Samimi-Rad; Mohsen Nasiri Toosi; Ali Masoudi-Nejad; Ali Najafi; Ramin Rahimnia; Fatemeh Asgari; Alireza Namazi Shabestari; Gholamreza Hassanpour; Seyed-Moayed Alavian; Freshteh Asgari
Journal:  Arch Virol       Date:  2012-06-13       Impact factor: 2.574

3.  Surveillance for acute viral hepatitis--United States, 2006.

Authors:  Annemarie Wasley; Scott Grytdal; Kathleen Gallagher
Journal:  MMWR Surveill Summ       Date:  2008-03-21

4.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

Review 5.  Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.

Authors:  Leonard B Seeff; Jay H Hoofnagle
Journal:  Clin Liver Dis       Date:  2003-02       Impact factor: 6.126

Review 6.  Rapid virologic response: a new milestone in the management of chronic hepatitis C.

Authors:  Fred Poordad; K Rajender Reddy; Paul Martin
Journal:  Clin Infect Dis       Date:  2008-01-01       Impact factor: 9.079

Review 7.  Systematic review: Asian patients with chronic hepatitis C infection.

Authors:  L H Nguyen; M H Nguyen
Journal:  Aliment Pharmacol Ther       Date:  2013-04-05       Impact factor: 8.171

Review 8.  Improving outcome in patients with hepatitis C virus genotype 4.

Authors:  Sanaa M Kamal
Journal:  Am J Gastroenterol       Date:  2007-09-26       Impact factor: 10.864

9.  The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users.

Authors:  K Bojovic; J Simonovic; N Katanic; I Milosevic; I Pesic; D Delic; N Svirtlih; D J Jevtovic
Journal:  Biomed Pharmacother       Date:  2013-03-30       Impact factor: 6.529

Review 10.  Hepatitis C genotype 4: What we know and what we don't yet know.

Authors:  Sanaa M Kamal; Imad A Nasser
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

View more
  8 in total

Review 1.  Epidemiology of hepatitis C virus in Iran.

Authors:  Reza Taherkhani; Fatemeh Farshadpour
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  The association between oral lichen planus and hepatitis C virus infection; a report from northeast of iran.

Authors:  Sina Gerayli; Zahra Meshkat; Alireza Pasdar; Pegah Mosannen Mozafari; Elham Banihashemi; Mohammad Amin Khajavi; Javid Rasekhi
Journal:  Jundishapur J Microbiol       Date:  2015-04-18       Impact factor: 0.747

Review 3.  Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the Eastern Mediterranean Regional Office of WHO (EMRO): A Systematic Review and Meta-Analysis.

Authors:  Farzin Sadeghi; Mostafa Salehi-Vaziri; Amir Almasi-Hashiani; Mohammad Gholami-Fesharaki; Reza Pakzad; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-04-19       Impact factor: 0.660

4.  Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users.

Authors:  Marzieh Jamalidoust; Mandana Namayandeh; Mohsen Moghadami; Mazyar Ziyaeyan
Journal:  Virol J       Date:  2017-07-11       Impact factor: 4.099

5.  Distribution of Hepatitis C Virus Genotypes in Patients with Major β-Thalassemia in Mashhad, Northeast Iran.

Authors:  Sanaz Ahmadi-Ghezeldasht; Zahra Badiei; Hamid Reza Sima; Mohammad Reza Hedayati-Moghaddam; Meysam Habibi; Mohsen Khamooshi; Ahmad Azimi
Journal:  Middle East J Dig Dis       Date:  2018-01-07

Review 6.  Oral Lichen Planus: an Overview of Potential Risk Factors, Biomarkers and Treatments

Authors:  Tahereh Nosratzehi
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

Review 7.  The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis.

Authors:  Hossein Ghaderi-Zefrehi; Mohammad Gholami-Fesharaki; Heidar Sharafi; Farzin Sadeghi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-08-23       Impact factor: 0.660

8.  Lack of Association between Oral Lichen Planus and Hepatitis B and C Virus Infection - a Report from Southeast Iran

Authors:  Tahereh Nosratzahi; Mehrab Raiesi; Bahareh Shahryari
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.